Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain tumor imaging study aims to find hidden cancer stem cells

NCT ID NCT01872221

Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a special MRI technique can identify the most aggressive parts of a glioblastoma brain tumor. Researchers took tissue samples from different areas of the tumor during surgery and tested them for cancer stem cells. The goal was to see if MRI markers match the biology of the tumor, which could help guide future treatments. 21 patients took part in this early-stage research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

21 people

The number who actually took part.

Start date

May 2013

Finished

Apr 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: First part of the study (Surgery and Imagery): 1. Surgical indication for patients who present radiological criteria of glioblastoma. 2. Patient who are ≥18 years old 3. Patient must have performance status between 0 and 2 on the ECOG Performance Scale 4. Life expectancy ≥ 3 months 5. Patient affiliated to social security regimen 6. Patient has voluntarily agreed to participate by giving written informed consent for the first part of the study. Second part of the study (Treatment and Biology): 1. Histologically confirmed glioblastoma 2. Patient must have performance status between 0 and 2 on the ECOG Performance Scale or 3 only is due to motor deficit. 3. Life expectancy ≥ 3 months 4. Patient affiliated to social security regimen 5. Patient has voluntarily agreed to participate by giving written informed consent for the second part of the study. Exclusion Criteria: First part of the study (Surgery and Imagery): 1. Patients who are not allowed to perform an MRI 2. Spectroscopic exam whose results are not contributive 3. Pregnant or nursing patient, 4. Patients under law protection 5. Patient who presents conditions that would interfere with cooperation with the requirements of the trial. 6. Patient who presents medical, severe or chronic biological or psychiatric conditions not allowing his enrolment in the study, according to the investigator's opinion Second part of the study (Treatment and Biology): 1.Biological material received in the lab more than 48 hours after surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioblastoma

Contacts and locations

Locations

  • CHU Rangueil

    Toulouse, 31000, France

  • Institut Claudius REGAUD

    Toulouse, 31052, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.